Medicare Enrolled
Dr. Charlene Lee, MD
Student in an Organized Health Care Education/Training Program · San Jose, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lee from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lee?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lee
Dr. Charlene Lee is a student in an organized health care education/training program specialist in San Jose, CA, with 15 years of NPI registration. Based on federal Medicare data, Dr. Lee performed 9,311 Medicare services across 652 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lee received a total of $14,335 from 67 pharmaceutical and/or device companies across 471 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in student in an organized health care education/training program. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lee is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice
▲ Top 2% volume in CA
$14,335 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,311
Medicare services
Top 2% in CA for student in an organized health care education/training program
652
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~621 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 6,800 | $0 | $1 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
590 | $1 | $5 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
548 | $80 | $160 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
407 | $16 | $45 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
301 | $109 | $200 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
156 | $120 | $206 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
118 | $1 | $1 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
102 | $140 | $300 |
| New patient office visit, complex (60-74 min) | 70 | $204 | $335 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
69 | $57 | $78 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
51 | $29 | $71 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
25 | $143 | $277 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $116 | $230 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
20 | $5 | $5 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
19 | $71 | $140 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
14 | $156 | $330 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.4% high complexity
83.2% medium
9.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,335
Total received (2018-2024)
Avg $2,048/year across 7 years
Top 3% in CA for student in an organized health care education/training program
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
67
Companies
471
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,395 (79.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,617 (18.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$322 (2.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,811
2023
$1,875
2022
$2,003
2021
$1,047
2020
$848
2019
$4,510
2018
$1,240
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$475
Astellas Pharma US Inc
$270
PFIZER INC.
$265
Novartis Pharmaceuticals Corporation
$211
Janssen Biotech, Inc.
$210
Coherus Biosciences Inc.
$147
Regeneron Healthcare Solutions, Inc.
$97
ABBVIE INC.
$96
Merck Sharp & Dohme LLC
$86
ARRAY BIOPHARMA INC
$74
GlaxoSmithKline, LLC.
$73
SOBI, INC
$67
Celgene Corporation
$61
Takeda Pharmaceuticals U.S.A., Inc.
$59
PROGENICS PHARMACEUTICALS, INC.
$53
Sirtex Medical Inc
$53
E.R. Squibb & Sons, L.L.C.
$48
Daiichi Sankyo Inc.
$47
TAIHO ONCOLOGY, INC.
$36
Deciphera Pharmaceuticals Inc.
$36
EMD Serono, Inc.
$34
Stemline Therapeutics Inc.
$34
Bayer Healthcare Pharmaceuticals Inc.
$34
Sumitomo Pharma America, Inc.
$33
Novocure Inc.
$32
Lilly USA, LLC
$30
PharmaEssentia USA Corporation
$29
Genmab U.S., Inc.
$28
Eisai Inc.
$25
Tempus AI, Inc
$25
BeiGene USA, Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
Top 3 companies account for 35.9% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$3,799
Novartis Pharmaceuticals Corporation
$1,656
PFIZER INC.
$1,032
Janssen Biotech, Inc.
$886
E.R. Squibb & Sons, L.L.C.
$723
Lilly USA, LLC
$524
Astellas Pharma US Inc
$448
Seagen Inc.
$369
Takeda Pharmaceuticals U.S.A., Inc.
$331
Merck Sharp & Dohme LLC
$305
Merck Sharp & Dohme Corporation
$270
GlaxoSmithKline, LLC.
$263
Celgene Corporation
$248
Rigel Pharmaceuticals, Inc.
$197
Amgen Inc.
$177
Boehringer Ingelheim Pharmaceuticals, Inc.
$154
Coherus Biosciences Inc.
$147
ARRAY BIOPHARMA INC
$144
Regeneron Healthcare Solutions, Inc.
$129
Insmed, Inc.
$125
Alexion Pharmaceuticals, Inc.
$125
Daiichi Sankyo Inc.
$121
Dova Pharmaceuticals
$110
ABBVIE INC.
$96
Intuitive Surgical, Inc.
$95
Eisai Inc.
$89
EMD Serono, Inc.
$84
Kite Pharma, Inc.
$79
Janssen Products, LP
$75
Janssen Pharmaceuticals, Inc
$74
Pharmacyclics LLC, An AbbVie Company
$71
Foundation Medicine, Inc.
$71
Progenics Pharmaceuticals, Inc.
$67
SOBI, INC
$67
Deciphera Pharmaceuticals Inc.
$66
Bayer HealthCare Pharmaceuticals Inc.
$61
Bayer Healthcare Pharmaceuticals Inc.
$58
Blueprint Medicines Corporation
$58
Sobi, Inc
$54
PROGENICS PHARMACEUTICALS, INC.
$53
Clovis Oncology, Inc.
$53
Sirtex Medical Inc
$53
Genentech USA, Inc.
$47
Seattle Genetics, Inc.
$47
Puma Biotechnology, Inc.
$45
ADC Therapeutics America, Inc.
$39
GENZYME CORPORATION
$37
TAIHO ONCOLOGY, INC.
$36
Stemline Therapeutics Inc.
$34
Elekta, Inc.
$34
Sumitomo Pharma America, Inc.
$33
Aveo Pharmaceuticals, Inc.
$32
Novocure Inc.
$32
PharmaEssentia USA Corporation
$29
Genmab U.S., Inc.
$28
CTI BioPharma Corp.
$27
Incyte Corporation
$26
Tempus AI, Inc
$25
EISAI INC.
$25
PUMA BIOTECHNOLOGY, INC.
$24
BeiGene USA, Inc.
$23
Blue Earth Diagnostics Limited
$22
PALETTE LIFE SCIENCES, INC.
$21
Janssen Scientific Affairs, LLC
$21
MorphoSys, US Inc.
$21
Gilead Sciences, Inc.
$16
MEDIVATION FIELD SOLUTIONS LLC
$4
Top 3 companies account for 45.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Arikayce · Axumin · BAVENCIO · BESREMI · BLENREP · BRAFTOVI · CALQUENCE · CYRAMZA · DARZALEX · DOPTELET · Da Vinci Surgical System · Doptelet · ELEKTA UNITY · ELIQUIS · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · FRUZAQLA · GAVRETO · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · INREBIC · JADENU · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LOQTORZI · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OJJAARA · OPDIVO · ORGOVYX · Optune Lua (NovoTTF-200T) · Orserdu · PADCEV · PLUVICTO · PROMACTA · PYLARIFY · Padcev · Pomalyst · QINLOCK · REBLOZYL · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · TAGRISSO · TALZENNA · TASIGNA · TECVAYLI · TEVIMBRA · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · Udenyca · VELCADE · VERZENIO · VONJO · VOTRIENT · Vonjo · Vyloy · XALKORI · XARELTO · XTANDI · Xtandi · ZEJULA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 3% for student in an organized health care education/training program in CA.
Geographic Context
Student in an organized health care education/training programs within 10 mi
3,143
Per 100K population
165.1
County median income
$159,674
Nearest hospital
REGIONAL MEDICAL CENTER OF SAN JOSE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lee is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement in the top 3% of CA peers, with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lee experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Lee performed 6,800 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lee receive payments from pharmaceutical companies?
Yes. Dr. Lee received a total of $14,335 from 67 companies across 471 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lee's costs compare to other student in an organized health care education/training programs in San Jose?
Dr. Lee's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lee) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Student In An Organized Health Care Education/training Programs in San Jose
Browse student in an organized health care education/training programs in San Jose ranked by procedure volume and transparency data.
Highest volume
Top Student In An Organized Health Care Education/training Programs in CA
Student in an organized health care education/training programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student In An Organized Health Care Education/training Programs in CA
Which CA student in an organized health care education/training programs receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology